These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27832030)

  • 21. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports.
    Chamorro-de-Vega E; Gimenez-Manzorro A; Sanjurjo M;
    Med Clin (Barc); 2018 Jul; 151(2):85-86. PubMed ID: 29295791
    [No Abstract]   [Full Text] [Related]  

  • 22. Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.
    Lenz DU; Crutcher EL; Greene EM
    J Pharm Pract; 2019 Apr; 32(2):231-235. PubMed ID: 29183252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C.
    Padidam S; Burke MT; Apple DB; Hu JK; Lin X
    JAMA Ophthalmol; 2019 May; 137(5):568-570. PubMed ID: 30920588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population.
    Tang L; Parker A; Flores Y; Dellario M; Dickson C; Amoroso A; Kottilil S; Wilson E
    J Viral Hepat; 2018 Feb; 25(2):205-208. PubMed ID: 28984059
    [No Abstract]   [Full Text] [Related]  

  • 25. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children.
    El-Shabrawi MHF; Kamal NM; El-Khayat HR; Kamal EM; AbdElgawad MMAH; Yakoot M
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1699-1704. PubMed ID: 29696674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
    Kwok RM; Ahn J; Schiano TD; Te HS; Potosky DR; Tierney A; Satoskar R; Robertazzi S; Rodigas C; Lee Sang M; Wiegel J; Patel N; Gripshover J; Hassan MA; Branch A; Smith CI
    Liver Transpl; 2016 Nov; 22(11):1536-1543. PubMed ID: 27543748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach.
    Johnson SW; Ammirati SR; Hartis CE; Weber SF; Morgan MR; Darnell TA; Silwal A; Schmidlin HN; Priest DH
    Int J Antimicrob Agents; 2017 Jun; 49(6):778-781. PubMed ID: 28389353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two Antiviral Drugs Approved For Adolescents With HCV.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
    [No Abstract]   [Full Text] [Related]  

  • 30. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
    El-Khayat HR; Kamal EM; El-Sayed MH; El-Shabrawi M; Ayoub H; RizK A; Maher M; El Sheemy RY; Fouad YM; Attia D
    Aliment Pharmacol Ther; 2018 Mar; 47(6):838-844. PubMed ID: 29349793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
    AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
    Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection.
    Latini A; Orsini D; Ambrifi M; Colafigli M; Zaccarelli M; Cristaudo A
    G Ital Dermatol Venereol; 2019 Oct; 154(5):593-594. PubMed ID: 29192474
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.
    Okubo T; Atsukawa M; Tsubota A; Toyoda H; Shimada N; Abe H; Kato K; Hayama K; Arai T; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kawamoto C; Iio E; Tanaka Y; Kumada T; Iwakiri K
    Hepatol Int; 2018 Mar; 12(2):133-142. PubMed ID: 29600429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
    Gentile I; Borgia G
    Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
    Gray E; O'Leary A; Bergin C; Cannon M; Courtney G; Crosbie O; De Gascun CF; Fanning LJ; Feeney E; Houlihan DD; Kelleher B; Lambert JS; Lee J; Mallon P; McConkey S; McCormick A; McKiernan S; McNally C; Murray F; Sheehan G; Stewart S; Walsh C; Norris S;
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):593-601. PubMed ID: 28276815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C Virus Infection in ESKD Patients.
    Ladino M; Roth D
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1735-1737. PubMed ID: 30065068
    [No Abstract]   [Full Text] [Related]  

  • 38. Case of Erythema Multiforme Drug Eruption Induced by Ledipasvir/Sofosbuvir.
    Wang Y; Zheng S
    Am J Ther; 2018; 25(5):e586-e587. PubMed ID: 30188425
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-HCV for porphyria cutanea tarda.
    Abdelmaksoud A
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.